Fibroblast Growth Factor-23 (FGF-23) and Its Correlation with Renal Function and Bone Mineral Markers in a Sample of Iraqi Patients with Chronic Kidney Disease and Those Undergoing Hemodialysis
Biomedical Research and Therapy · 31.10.2026 · 13 (10) · 9141-9152
DOI: 10.15419/bmrat.v13i10.1111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Research and Therapy, online erschienen am 31.10.2026. Verfasst von Abdullah Abdulsattar Raeef und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Fibroblast growth factor-23 (FGF-23) plays a central role in mineral metabolism and is implicated in the pathogenesis of chronic kidney disease–mineral and bone disorder (CKD-MBD). This study aimed to evaluate the relationships between serum FGF-23 concentrations and clinical, renal function, and bone mineral parameters in pre-dialysis chronic renal failure (CRF) patients and maintenance hemodialysis (HD) patients in an Iraqi cohort.
Methods
This cross-sectional study enrolled 90 participants divided into three equal groups (n = 30 per group): pre-dialysis CRF patients (CKD stages 3–5), maintenance HD patients, and age- and sex-matched healthy controls. Venous blood samples were analyzed for serum intact FGF-23, phosphorus, calcium, parathyroid hormone (PTH), total vitamin D, urea, creatinine, and uric acid. Group differences, bivariate associations, and diagnostic accuracy were assessed using one-way analysis of variance (ANOVA) with Bonferroni post-hoc correction, Pearson’s correlation coefficient, and receiver operating characteristic (ROC) curve analysis, respectively.
Results
Serum FGF-23 levels were significantly elevated in HD patients compared with healthy controls (216.5 ± 30.92 vs. 134.7 ± 17.08 pg/mL; p = 0.011), accompanied by marked increases in serum phosphorus and PTH and significantly reduced vitamin D and calcium concentrations. Across the study cohort, serum FGF-23 exhibited a moderate positive correlation with PTH (r = 0.451, p = 0.0001) and a weak positive correlation with serum creatinine (r = 0.183, p = 0.042), whereas no significant correlations were observed with serum phosphorus, calcium, or vitamin D. In ROC curve analysis discriminating pre-dialysis CRF patients from controls, the area under the curve (AUC) values were 0.812 for phosphorus, 0.785 for vitamin D, 0.710 for PTH, and 0.635 for FGF-23. In discriminating HD patients from controls, AUC values were 0.874 for phosphorus, 0.774 for PTH, 0.733 for vitamin D, and 0.729 for FGF-23.
Conclusions
Elevated circulating FGF-23 concentrations are associated with impaired renal function and secondary hyperparathyroidism, particularly among patients receiving maintenance hemodialysis. Although serum FGF-23 reflects disturbances in the bone–parathyroid–kidney axis in advanced renal disease, larger longitudinal studies are warranted to establish its independent prognostic value for CKD progression and clinical outcomes.
Zitieren
APA
Raeef, A. A., Ayada, B. H., Dylan, B. A., & Saleh, S. A. (2026). Fibroblast Growth Factor-23 (FGF-23) and Its Correlation with Renal Function and Bone Mineral Markers in a Sample of Iraqi Patients with Chronic Kidney Disease and Those Undergoing Hemodialysis. Biomedical Research and Therapy, 13(10), 9141-9152. https://doi.org/10.15419/bmrat.v13i10.1111
Vancouver
Raeef AA, Ayada BH, Dylan BA, Saleh SA. Fibroblast Growth Factor-23 (FGF-23) and Its Correlation with Renal Function and Bone Mineral Markers in a Sample of Iraqi Patients with Chronic Kidney Disease and Those Undergoing Hemodialysis. Biomedical Research and Therapy. 2026;13(10):9141-9152. doi:10.15419/bmrat.v13i10.1111
BibTeX
@article{Raeef2026,
author = {Raeef, Abdullah Abdulsattar and Ayada, Baida Hussein and Dylan, Bilal A. and Saleh, Saif Abduljabbar},
title = {Fibroblast Growth Factor-23 (FGF-23) and Its Correlation with Renal Function and Bone Mineral Markers in a Sample of Iraqi Patients with Chronic Kidney Disease and Those Undergoing Hemodialysis},
journal = {Biomedical Research and Therapy},
year = {2026},
volume = {13},
number = {10},
pages = {9141--9152},
doi = {10.15419/bmrat.v13i10.1111}
}
EUVIMED